Abstract: Systems and methods for providing contextual interaction with connected devices are described. A mobile device having a display that presents a user interface enabling access to functionalities provided by connected devices. The user interface may be updated as various contextually-related data is received. For example, data representing a current position of the mobile device, such as Bluetooth low energy beacon signals, WiFi signals, and the like, may be monitored. In response to determining that the current position is within a threshold proximity of a first location, the user interface may be updated to emphasize a first location interface corresponding to the first location over interfaces corresponding to other locations.

Abstract: Techniques for providing status information of a defined location are described. Data indicative of signal strength associated with radio frequency (RF) signals received by one or more devices communicating via a wireless communications protocol is accessed. A baseline signal strength profile based on the data is determined. The data indicative of signal strength associated with RF signals received by the one or more devices is monitored. Based on a comparison of the monitored data to the baseline signal strength profile, a presence of at least one person in a vicinity of the one or more devices is determined. At least one action based on the determined presence is initiated.

Abstract: Techniques for providing status information of a defined location are described. Data indicative of signal strength associated with radio frequency (RF) signals received by one or more devices communicating via a wireless communications protocol is accessed. A baseline signal strength profile based on the data is determined. The data indicative of signal strength associated with RF signals received by the one or more devices is monitored. Based on a comparison of the monitored data to the baseline signal strength profile, a presence of at least one person in a vicinity of the one or more devices is determined. At least one action based on the determined presence is initiated.

Abstract: Techniques for providing status information of a defined location are described. Data indicative of signal strength associated with radio frequency (RF) signals received by one or more devices communicating via a wireless communications protocol is accessed. A baseline signal strength profile based on the data is determined. The data indicative of signal strength associated with RF signals received by the one or more devices is monitored. Based on a comparison of the monitored data to the baseline signal strength profile, a presence of at least one person in a vicinity of the one or more devices is determined. At least one action based on the determined presence is initiated.

Abstract: Systems and methods for providing contextual interaction with connected devices are described. A mobile device having a display that presents a user interface enabling access to functionalities provided by connected devices. The user interface may be updated as various contextually-related data is received. For example, data representing a current position of the mobile device, such as Bluetooth low energy beacon signals, WiFi signals, and the like, may be monitored. In response to determining that the current position is within a threshold proximity of a first location, the user interface may be updated to emphasize a first location interface corresponding to the first location over interfaces corresponding to other locations.

Abstract: A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract: Techniques for providing status information of a defined location are described. Data indicative of signal strength associated with radio frequency (RF) signals received by one or more devices communicating via a wireless communications protocol is accessed. A baseline signal strength profile based on the data is determined. The data indicative of signal strength associated with RF signals received by the one or more devices is monitored. Based on a comparison of the monitored data to the baseline signal strength profile, a presence of at least one person in a vicinity of the one or more devices is determined. At least one action based on the determined presence is initiated.

Abstract: Systems and methods for providing contextual interaction with connected devices are described. A mobile device having a display that presents a user interface enabling access to functionalities provided by connected devices. The user interface may be updated as various contextually-related data is received. For example, data representing a current position of the mobile device, such as Bluetooth low energy beacon signals, WiFi signals, and the like, may be monitored. In response to determining that the current position is within a threshold proximity of a first location, the user interface may be updated to emphasize a first location interface corresponding to the first location over interfaces corresponding to other locations.

Abstract: A series of substituted 3,4-di-hydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.

Abstract: The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

Abstract: The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.

Abstract: The present invention is directed to therapeutic compounds which have dual activity as agonists of GPR119 and inhibitors of DPP-IV and are useful for the treatment of metabolic disorders including type II diabetes.

Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.

Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, exhibit 5-HT1A agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are useful for the treatment of obesity.